Drug Profile
Research programme: HDM2 inhibitors - Cyclacel Pharmaceuticals
Alternative Names: CYC 700 series; p53/HDM2 inhibitors research programme - Cyclacel PharmaceuticalsLatest Information Update: 16 Feb 2010
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 25 May 2005 This programme is still in active development
- 02 Mar 2004 Compounds from the hdm2 modulator research programme are available for licensing worldwide (http://www.cyclacel.com)